Abbvie Inc.

Anthony Mastracchio

Thomas Dale Penning

Chunqiu Lai

Andrew J Souers

Zhi-Fu Tao

Keith W Woods

Milan Bruncko

Julie M Miyashiro

Xiaohong Song

Yunsong Tong

George A Doherty

Xilu Wang

Michael D Wendt

Aaron R Kunzer

Richard F Clark

Michael Michaelides

Todd M Hansen

Alan S Florjancic

Michael L Curtin

Andrew S Judd

Robin R Frey

Zhiqin Ji

Jianchun Gong

Virajkumar B Gandhi

Mark Mills

Andrew William Phillips

Cheng Ji

Guidong Zhu

Viraj B Gandhi

Rajeev Goswami

Madhu Babu Dabbeeru

Omprakash Reddy Iguturi

Roberto M Risi

Juliem Miyashiro

Puneet Kumar

The present disclosure provides for compounds of the general Formula (I)

Thiazolo[5,4-b]pyridine MALT-1 inhibitors

The present disclosure provides for compounds of formula (I) wherein A, A, A, A, A, A, A, R, R, R, R, R, R, R, R, R, R, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

Macrocyclic MCL-1 inhibitors and methods of use

Disclosed are compounds of Formula (IIa), wherein R, R, R, R, R, R, R, and Rare as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R, R, R, R, and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

Pyridopyrimidinone inhibitors of kinases

Disclosed are compound of Formula (Ia), wherein R, R, R, J, Q, X, Y and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (Ia).

Pyridine CDK9 kinase inhibitors

Compounds of formula (I), and pharmaceutical acceptable salts thereof, which inhibit the activity of kinases such as Wee-1 kinase are described. Also described are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Disclosed are compound of Formula (Ia), wherein R, R, R, R, J, L, T, X, Y, and Z are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions, comprising one or more compounds of Formula (Ia).

CDK9 kinase inhibitors

Growing community of inventors

Waukegan, IL, United States of America

Anthony Mastracchio